drugset / Trial / NCT06539663

The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients

NCT06539663 ↗

Phase 2/3 Completed 5 enrolled Farwaniya Hospital
NaSingle-groupOpen-labelTreatment

Summary

Case series of 5 ICU patients in Farwaniya Hospital who developed exposure keratitis and a subsequent small corneal perforation between April 2022 and April 2024. The investigators highlight the non-surgical role of OmniLenz® in the treatment of small corneal perforations secondary to exposure keratitis. The inclusion criteria were corneal perforation less than 1mm in size, positive culture \& sensitivity results and showing initial improvement on topical antibiotic eye drops.

Timeline

Start
2022-04-10
Primary completion
2024-02-10
Completion
2024-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject OmniLenz® Unknown — —